Mast Cells, Histamine, and Perimenopause Explained | MCAS, Anxiety, Estrogen

Rubin emphasizes that patients often come with a preconceived MCAS diagnosis but lack objective tracking. He urges women to map out the cyclical nature of their symptoms, as many allergic and mood complaints peak before menstruation. This simple tool can change the conversation with a physician from 'I think I have MCAS' to 'here is the pattern, could histamine be involved?' He considers it foundational, because jumping straight to daily antihistamines without understanding timing may mask the underlying trigger and complicate the picture.

Rubin's real-world observation began with chronic hives patients; he noticed women on Allegra + Pepcid reported mood and gut improvements beyond skin. He sees the combination as a 'Maverick' approach — mechanistically sound, anecdotally striking, but devoid of clinical trial data. He explains the receptor specificity: H1 blockers handle classic allergy, H2 blockers like famotidine are primarily antacids but also reside on mast cells and blood vessels. He explicitly rejects Benadryl for long-term use because of anticholinergic dementia risk, and Zyrtec because of its sedating profile in many people (including himself). He urges tapering off gradually to avoid severe pruritus. He sees this as a bridge therapy while we await proper OBGYN-immunology collaborative trials.

Rubin discusses cromolyn as one of the most effective tools he has for MCAS patients with predominant abdominal complaints. He notes that the titration challenge is real: pushing the dose too fast causes the very diarrhea it's meant to treat, because the mast cells are destabilized by the introduction of the drug before they become tolerant. He considers it a powerful test — if patients improve on cromolyn, it strongly supports a mast cell-driven pathology. However, it requires a motivated patient and careful coaching, and it is not a first-line self-experiment the way OTC antihistamines might be.

Rubin walks through the three diagnostic criteria for MCAS: (1) severe recurrent symptoms in ≥2 organ systems (skin flushing, hives, swelling; GI bloating, pain, diarrhea; cardiovascular POTS-like tachycardia; neuropsychiatric brain fog/fatigue); (2) lab evidence of mast cell activation; (3) clinical response to mast cell-targeted therapy. He warns that many symptoms overlap with perimenopause, so he starts by ruling out menopause and thyroid disease. The lab work is notoriously difficult to time and interpret; he has almost never seen a positive leukotriene or 24-hour histamine test in his community practice, but prostaglandin D2 spot tests are often positive. He advises physicians to order tryptase levels ahead of time so they are readily available when patients flare. He emphasizes that patients should not feel written off after a single negative test, drawing a parallel to autoimmune serologies that may take years to turn positive.

Rubin describes this withdrawal itch as 'ants crawling on their skin,' a phenomenon he has seen enough to warn about explicitly. He notes there is no standardized tapering schedule, and that coordination with the prescribing physician is essential. He positions this as part of the long-term risk-benefit discussion for any woman considering chronic H1/H2 blockade for hormonal symptoms — the commitment to smoothly exit the therapy is part of the upfront plan.

Rubin observed that many women report their allergies, hives, or even mood symptoms spike in the days before menstruation. Mechanistically, estrogen not only stimulates mast cell degranulation but also slows histamine breakdown, while progesterone acts as a brake. In the luteal phase, estrogen remains elevated and progesterone declines, creating a pro-histamine window. He is convinced enough of the link that he is filming an educational video to help the public understand why their asthma, eczema, or urticaria might behave cyclically. He frames this as an opportunity to validate patients' experiences and to promote cycle tracking as a diagnostic tool.

Rubin recounts that when he prescribed the Allegra–Pepcid combination for chronic hives, women would return reporting that other symptoms — particularly mood — also improved. He began connecting the dots between H2 receptors in the gut, blood vessels, and mast cells, and the broader role of histamine in the brain (sleep, mood, appetite). He emphasizes repeatedly that no randomized trials exist for PMDD, endometriosis, perimenopause, or menopause, making this an off-label, experimental approach built on 'building the ship and riding it at the same time.' He advocates believing women when they say it helps, because the mechanism — estrogen-driven mast cell activation and histamine lingering — plausibly explains the improvement. He also stresses that anyone trying this should do so one step at a time, keep a symptom journal, and involve their physician to rule out thyroid disease or other mimics.

Rubin explains that diphenhydramine's anticholinergic properties are associated with dementia in long-term users, and he flatly states 'I never recommend Benadryl for this approach.' He describes his own sensitivity: taking even half a Zyrtec makes him feel as sedated as Benadryl. He therefore directs patients toward Allegra (fexofenadine) or Claritin (loratadine), which are less likely to cross the blood-brain barrier and have a better safety profile for chronic, daily use. He still cautions that even these newer antihistamines may increase hunger and cause weight gain — 10 to 20 lbs in some — and that abrupt discontinuation can trigger severe itching akin to 'ants crawling on the skin.'

Rubin explains the enzyme diamine oxidase (DAO) is supposed to break down histamine, but the clinical evidence for supplementation is weak. He references a double-blind, randomized, placebo-controlled trial where people who believed they had histamine intolerance were given either histamine or a placebo; there was virtually no difference in symptoms between the groups, suggesting the intolerance may be something else — possibly MCAS or another mechanism. He also notes that quercetin shows antihistaminic activity in vitro, but the optimal dose and safety profile are unknown, and because supplements aren't FDA-regulated, the actual milligram content is unreliable. On diets: he acknowledges single-food elimination trials done methodically can be useful, but sweeping low-histamine diets are not standardized and can provoke disordered eating and anxiety. His stance is that he cannot generally recommend these approaches on social media given the safety unknowns.